Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798915 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00798915 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00798915, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also known as adult onset or non-insulin-dependent diabetes. This study is being conducted to determine whether a hormone called xenin-25 can restore the activity of GIP in persons with T2DM.
Interventions
- DRUG Placebo
- DRUG Glucose-dependent Insulinotropic Polypeptide (GIP)
- DRUG Xenin-25
- DRUG Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00798915
The ClinicalTrials.gov registry entry for NCT00798915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00798915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00798915 about?
NCT00798915 is a clinical study titled "Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus". An intestinal hormone called Glucose-dependent Insulinotropic Polypeptide (GIP) is released into the blood immediately after ingestion of a meal and plays an important role in regulating blood sugar levels. However, GIP is not active in persons with type 2 diabetes mellitus (T2DM) which is also know...
What is the current status of trial NCT00798915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00798915?
The interventions under investigation include: Placebo (DRUG), Glucose-dependent Insulinotropic Polypeptide (GIP) (DRUG), Xenin-25 (DRUG), Glucose-dependent Insulinotropic Polypeptide plus Xenin-25 (DRUG).
Who is sponsoring clinical trial NCT00798915?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.